Inge Kroidl, Petra Clowes, Klaus Reither, Bariki Mtafya, Gabriel Rojas-Ponce, Elias N. Ntinginya, Mariam Kalomo, Lilian T. Minja, Dickens Kowuor, Elmar Saathoff, Arne Kroidl, Norbert Heinrich, Leonard Maboko, Matthew Bates, Justin O'Grady, Alimuddin Zumla, Michael Hoelscher, Andrea Rachow
We evaluated the diagnostic performance of two tests based on the release of lipoarabinomannan (LAM) into the urine, the MTB-LAM-ELISA assay and the Determine TB-LAM-strip assay, in children with suspected tuberculosis (TB) in a high TB/HIV-prevalence setting. In a prospective study, 132 children with suspected active TB were assigned to diagnostic subgroups. Urine samples were subjected to testing by both assays to ascertain sensitivity and specificity. Host factors associated with positive LAM results were investigated and LAM excretion ..........
Published at: 2015-08-31
Alimuddin Zumla, Jeremiah Chakaya, Michael Hoelscher, Francine Ntoumi, Roxana Rustomjee, Cristina Vilaplana, Dorothy Yeboah-Manu, Voahangy Rasolofo, Paula Munderi, Nalini Singh, Eleni Aklillu, Nesri Padayatchi, Eusebio Macete, Nathan Kapata, Modest Mulenga, Gibson Kibiki, Sayoki Mfinanga, Thomas Nyirenda, Leonard Maboko, Alberto Garcia-Basteiro, Niaina Rakotosamimanana, Matthew Bates, Peter Mwaba, Klaus Reither, Sebastien Gagneux, Sarah Edwards, Elirehema Mfinanga, Salim Abdulla, Pere-Joan Cardona, James B.W. Russell, Vanya Gant, Mahdad Noursadeghi, Paul Elkington, Maryline Bonnet, Clara Menendez, Tandakha N. Dieye, Bassirou Diarra, Almoustapha Maiga, Abraham Aseffa, Shreemanta Parida, Christian Wejse, Eskild Petersen, Pontiano Kaleebu, Matt Oliver, Gill Craig, Tumena Corrah, Leopold Tientcheu, Martin Antonio, Martin Rao, Timothy D. McHugh, Aziz Sheikh, Giuseppe Ippolito, Gita Ramjee, Stefan H. E. Kaufmann, Gavin Churchyard, Andrie Steyn, Martin Grobusch, Ian Sanne, Neil Martinson, Rajhmun Madansein, Robert J. Wilkinson, Bongani Mayosi, Marco Schito, Robert S. Wallis & Markus Maeurer
The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.
Published at: 2015-07-17
Authors: Lindsay Wieczorek, Shelly J. Krebs, Vaniambadi Kalyanaraman, Stephen Whitney, Sodsai Tovanabutra, Carlos G. Moscoso, Eric Sanders-Buell, Constance Williams, Bonnie Slike, Sebastian Molnar, Vincent Dussupt, S. Munir Alam, Agnes-Laurence Chenine, Tina Tong, Edgar L. Hill, Hua-Xin Liao, Michael Hoelscher, Leonard Maboko, Susan Zolla-Pazner, Barton F. Haynes, Michael Pensiero, Francine McCutchan, Shawyon Malek-Salehi, R. Holland Cheng, Merlin L. Robb, Thomas VanCott, Nelson L. Michael, Mary A. Marovich, Carl R. Alving, Gary R. Matyas, Mangala Rao, Victoria R. Polonis
Eliciting broadly reactive functional antibodies remains a challenge in human immunodeficiency virus type 1 (HIV-1) vaccine development that is complicated by variations in envelope (Env) subtype and structure. The majority of new global HIV-1 infections are subtype C, and novel antigenic properties have been described for subtype C Env proteins. Thus, an HIV-1 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) was.............
Published at: 2015-07-08
Authors: Rodney Dawson MD a, Andreas H Diacon MD b e, Dr Daniel Everitt MD f, Christo van Niekerk MD g, Peter R Donald MD c, Divan A Burger MCom h i, Robert Schall PhD h i, Melvin Spigelman MD f, Almari Conradie MPh g, Kathleen Eisenach PhD j, Amour Venter NatDipMicr d k, Prudence Ive FCP[SA] l, Liesl Page-Shipp MBBCh n, Ebrahim Variava MD m, Klaus Reither MD o p, Nyanda E Ntinginya MD q, Alexander Pym MD r, Florian von Groote-Bidlingmaier MD e, Carl M Mendel MD f
New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 weeks of treatment.
Published at: 2015-05-08
Patricia. J. Munseri ,Arne Kroidl ,Charlotta Nilsson,Agricola Joachim,Christof Geldmacher,Philipp Mann,Candida Moshiro,Said Aboud,Eligius Lyamuya,Leonard Maboko,Marco Missanga,Bahati Kaluwa,Sayoki Mfinanga,Lilly Podola,Asli Bauer,Karina Godoy-Ramirez,Mary Marovich,Bernard Moss,Michael Hoelscher,Frances Gotch,Wolfgang Stöhr,Richard Stout,Sheena McCormack,Britta Wahren,Fred Mhalu,Merlin L. Robb,Gunnel Biberfeld,Eric Sandström,Muhammad Bakari
Intradermal priming with HIV-1 DNA plasmids followed by HIV-1MVA boosting induces strong and broad cellular and humoral immune responses. In our previous HIVIS-03 trial, we used 5 injections with 2 pools of HIV-DNA at separate sites for each priming immunization. The present study explores whether HIV-DNA priming can be simplified by reducing the number of DNA injections and administration of combined versus separated plasmid pools.
Published at: 2015-04-15
Norbert Heinrich ,Tatjana Dill ,Gerhard Dobler,Petra Clowes,Inge Kroidl,Mandy Starke,Nyanda Elias Ntinginya,Leonard Maboko,Thomas Löscher,Michael Hoelscher,Elmar Saathoff
Rickettsioses are endemic in sub-Sahara Africa. Burden of disease, risk factors and transmission are hitherto sparsely described.
Published at: 2015-04-07
Norbert Heinrich, Rodney Dawson, Jeannine du Bois, Kim Narunsky, Gary Horwith, Andrew J. Phipps, Carol A. Nacy, Rob E. Aarnoutse, Martin J. Boeree, Stephen H. Gillespie, Amour Venter, Sonja Henne, Andrea Rachow, Patrick P. J. Phillips, Michael Hoelscher, Andreas H. Diacon, on behalf of the Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) on behalf of the Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA), Anna Maria Mekota, Norbert Heinrich, Andrea Rachow, Elmar Saathoff, Michael Hoelscher, Stephen Gillespie, Angela Colbers, Georgette Plemper van Balen, Rob Aarnoutse, Martin Boeree, Anna Bateson, Timothy McHugh, Kasha Singh, Robert Hunt, Alimuddin Zumla, Andrew Nunn, Patrick Phillips, Sunita Rehal, Rodney Dawson, Kim Narunsky, Andreas Diacon, Jeannine du Bois, Amour Venter, Sven Friedrich, Ian Sanne, Karla Mellet, Gavin Churchyard, Salome Charalambous, Peter Mwaba, Nyanda Elias, Chacha Mangu, Gabriel Rojas-Ponce, Bariki Mtafya, Leonard Maboko, Lilian Tina Minja, Mohamed Sasamalo, Klaus Reither, Levan Jugheli, Noel Sam, Gibson Kibiki, Hadija Semvua, Stellah Mpagama, Abraham Alabi, Ayola Akim Adegnika, Evans Amukoye, Alphonse Okwera
SQ109, an asymmetrical diamine, is a novel anti-TB drug candidate. This first study in patients was done to determine safety, tolerability, pharmacokinetics and bacteriological effect of different doses of SQ109 alone and in combination with rifampicin when administered over 14 days.
Published at: 2015-01-27